Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy
Medical Physics · 2024
DOI: 10.1002/mp.17067 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Medical Physics, 2024. Verfasst von Natalia Lutsik und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Glioblastoma, Diffusion Magnetic Resonance Imaging, Radiotherapy, Image-Guided, Phantoms, Imaging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
Background
MRI‐Linac systems enable daily diffusion‐weighed imaging (DWI) MRI scans for assessing glioblastoma tumor changes with radiotherapy treatment.
Purpose
Our study assessed the image quality of echoplanar imaging (EPI)‐DWI scans compared with turbo spin echo (TSE)‐DWI scans at 0.35 Tesla (T) and compared the apparent diffusion coefficient (ADC) values and distortion of EPI‐DWI on 0.35 T MRI‐Linac compared to high‐field diagnostic MRI scanners.
Methods
The calibrated National Institute of Standards and Technology (NIST)/Quantitative Imaging Biomarkers Alliance (QIBA) Diffusion Phantom was scanned on a 0.35 T MRI‐Linac, and 1.5 T and 3 T MRI with EPI‐DWI. Five patients were scanned on a 0.35 T MRI‐Linac with a TSE‐DWI sequence, and five other patients were scanned with EPI‐DWI on a 0.35 T MRI‐Linac and a 3 T MRI. The quality of images was compared between the TSE‐DWI and EPI‐DWI on the 0.35 T MRI‐Linac assessing signal‐to‐noise ratios and presence of artifacts. EPI‐DWI ADC values and distortion magnitude were measured and compared between 0.35 T MRI‐Linac and high‐field MRI for both phantom and patient studies.
Results
The average ADC differences between EPI‐DWI acquired on the 0.35 T MRI‐Linac, 1.5 T and 3 T MRI scanners and published references in the phantom study were 1.7%, 0.4% and 1.0%, respectively. Comparing the ADC values based on EPI‐DWI in glioblastoma tumors, there was a 3.36% difference between 0.35 and 3 T measurements. Susceptibility‐induced distortions in the EPI‐DWI phantoms were 0.46 ± 1.51 mm for 0.35 MRI‐Linac, 0.98 ± 0.51 mm for 1.5 T MRI and 1.14 ± 1.88 mm for 3 T MRI; for patients ‐0.47 ± 0.78 mm for 0.35 T and 1.73 ± 2.11 mm for 3 T MRIs. The mean deformable registration distortion for a phantom was 1.1 ± 0.22 mm, 3.5 ± 0.39 mm and 4.7 ± 0.37 mm for the 0.35 T MRI‐Linac, 1.5 T MRI, and 3 T MRI scanners, respectively; for patients this distortion was –0.46 ± 0.57 mm for 0.35 T and 4.2 ± 0.41 mm for 3 T. EPI‐DWI 0.35 T MRI‐Linac images showed higher SNR and lack of artifacts compared with TSE‐DWI, especially at higher b ‐values up to 1000 s/mm 2 .
Conclusion
EPI‐DWI on a 0.35 T MRI‐Linac showed superior image quality compared with TSE‐DWI, minor and less distortions than high‐field diagnostic scanners, and comparable ADC values in phantoms and glioblastoma tumors. EPI‐DWI should be investigated on the 0.35 T MRI‐Linac for prediction of early response in patients with glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Radiation Medicine & Applied Sciences, UC San Diego Health, La Jolla, California, USA.
- Neuro-Oncology division, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Former ViewRay, Inc., Ohio, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
Zitieren
APA
Lutsik, N., Nejad-Davarani, S. P., Valderrama, A., Herr, J., Maziero, D., Cullison, K., Azzam, G. A., Kubicek, G. J., Meshman, J., de la Fuente, M. I., Armstrong, T., & Mellon, E. A. (2024). Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy. Medical Physics. https://doi.org/10.1002/mp.17067
Vancouver
Lutsik N, Nejad-Davarani SP, Valderrama A, Herr J, Maziero D, Cullison K, et al. Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy. Medical Physics. 2024. doi:10.1002/mp.17067
BibTeX
@article{Lutsik2024,
author = {Lutsik, Natalia and Nejad-Davarani, Siamak P and Valderrama, Alessandro and Herr, Janette and Maziero, Danilo and Cullison, Kaylie and Azzam, Gregory A and Kubicek, Gregory J and Meshman, Jessica and de la Fuente, Macarena I and Armstrong, Tess and Mellon, Eric A},
title = {Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy},
journal = {Medical Physics},
year = {2024},
doi = {10.1002/mp.17067}
}
EUVIMED